Therefore, we have generated a panel of CRISPR-Cas9 KO MDA-MB-231 triple-negative breast cancer cell lines for CAPN1, CAPN2, or CAPNS1 genes, which provide models for complete pharmacological inhibition of calpain-1, calpain-2, or both, respectively. The gene discussed is CAPN2; the disease is triple-negative breast carcinoma.